ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BMEA / news
MREO (37) ATNM (43) ELTX (28) HOWL (42) ⌘ Pro Terminal →

Why BMEA Stock surged +3.19% Today — RQD Quant Desk Flash

$0.66 +3.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.66

Biomea Fusion Inc. (BMEA) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $46.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BMEA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BMEA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Biomea Fusion Inc. (NASDAQ: BMEA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.66 (+3.19% 1D, market cap $46.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BMEA ranks #806 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BMEA compare to MREO and ATNM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMEA carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and ATNM (Actinium Pharmaceuticals Inc. (Delaware)) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M). Among the 5-stock peer group, BMEA leads on earnings multiple (N/A) while BMEA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BMEA?
▼

Per BMEA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840439), Biomea Fusion Inc. generated $233.8M in revenue (-42.0% YoY), -$61.8M in net income, and -$70.4M in free cash flow against $58.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.66 (+0.38%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (4)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$2 Bull$1 Base$0 Bear
📬 FREE BMEA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BMEA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY BMEA SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 29 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$1.26-41.3% Next Q
Q2 (-2Q)
35
Grade E$0.74-13.5% Next Q
Q3 (-1Q)
33
Grade E$0.64+3.1% Next Q
Current
30
Grade E$0.66-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BMEA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BMEA currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($0.69) forces dealer call-delta covering toward $2.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BMEA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BMEA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why BMEA Stock surged +3.19% Today — RQD Quant Desk Flash

Biomea Fusion Inc. (BMEA) surged +3.19% to $0.66, trading at 7% of its 52-week range ($0.55 – $2.24). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 7% of its 52-week range ($0.55 – $2.24) with RSI-14 at 29 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.66 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BMEA Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BMEA)

  • ✓Walkthrough of BMEA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BMEA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.41%📐 HORIZONTAL RANGE
2026-11-03O $0.62H $0.66L $0.62C $0.66VOL 1.11M
RES: $2.43SUP: $0.50SMA50: $1.32SMA200: $1.37
$2.18$1.74$1.29$0.85$0.41RES $2.43SUP $0.50$0.662026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMEA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BMEA Butterfly Map → + Track BMEA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -42.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BMEA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BMEA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BMEA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMEA)

Health Care Rank #806 of 1015 ⚔️ MREO vs BMEA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BMEA vs. MREO, ATNM, ELTX, HOWL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Biomea Fusion Inc. (BMEA) ranks #806 by composite RQD confidence (30/100, grade E) and #756 by equity capitalization ($46.4M). Within this direct 5-issuer industry benchmark cohort, BMEA leads on earnings valuation at N/A trailing P/E, while BMEA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with BMEA at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BMEA ACTIVE
Biomea Fusion Inc.
E 30/100 — — -35.0% +3.19% $46.4M Benchmark Subject
MREO
Mereo BioPharma Group plc
D- 37/100 — — -35.0% +0.17% $46.2M /mreo-vs-bmea →
ATNM
Actinium Pharmaceuticals Inc. (Delaware)
D- 43/100 — — -35.0% -3.38% $46.5M /atnm-vs-bmea →
ELTX
Elicio Therapeutics Inc.
E 28/100 — — -35.0% -5.36% $45.5M /eltx-vs-bmea →
HOWL
Werewolf Therapeutics Inc.
D- 42/100 — — -35.0% +6.48% $47.9M /howl-vs-bmea →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840439 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biomea Fusion Inc. (BMEA) reported GAAP revenue of $233.8M (-42.0% vs. FY2024 revenue of $403.4M , and -33.8% cumulative change since FY2023) , GAAP net income of -$61.8M, operating cash flow of -$70.4M, and free cash flow of -$70.4M (+41.5% YoY). On the balance sheet, BMEA closed FY2025 with $58.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $233.8M -$61.8M -$70.4M -$70.4M $58.6M —
FY2024 (FY) 2024-12-31 $403.4M -$138.4M -$119.9M -$120.3M $79.9M —
FY2023 (FY) 2023-12-31 $353.2M -$117.3M -$96.6M -$96.6M — —

3. BMEA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMEA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Biomea Fusion Inc. (NASDAQ: BMEA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.66 (+3.19% 1D, market cap $46.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BMEA ranks #806 in composite RQD confidence.

How does BMEA compare to MREO and ATNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMEA carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and ATNM (Actinium Pharmaceuticals Inc. (Delaware)) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M). Among the 5-stock peer group, BMEA leads on earnings multiple (N/A) while BMEA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BMEA?

Per BMEA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840439), Biomea Fusion Inc. generated $233.8M in revenue (-42.0% YoY), -$61.8M in net income, and -$70.4M in free cash flow against $58.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BMEA trading relative to its 50-day, 200-day, and 52-week technical levels?

BMEA last traded at $0.66 (+3.19% on volume of 792,820 shares), positioning the stock -50.00% below its 50-day simple moving average ($1.32) and -51.82% below its 200-day simple moving average ($1.37). Across its 52-week range of $0.55 to $2.24, BMEA sits at the 6.5% percentile with a 14-day RSI of 29.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.74).

Direct Sub-Reports: BMEA RQD Cockpit BMEA 12M Forecast BMEA Earnings & Move BMEA Dividends & DRIP BMEA Insiders & 13F BMEA Whale Options BMEA Profit Sankey BMEA News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

BMEA — Biomea Fusion Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Biomea Fusion Inc. (BMEA) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.66 (+3.19% 1D, market capitalization $46.4M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Biomea Fusion Inc. (BMEA) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Biomea Fusion Inc. (BMEA) reported $233.8M in annual revenue (up from $403.4M in FY2024, -42.0% YoY) and -$61.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($353.2M revenue, -$117.3M net income) through FY2025, BMEA scaled operating cash flow to -$70.4M and free cash flow to -$70.4M, backed by $58.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.55 – $2.24 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BMEA carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can BMEA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $233.8M and free cash flow of -$70.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BMEA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BMEA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Biomea Fusion Inc. (BMEA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BMEA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BMEA Bull vs. Bear Conversation Board — What's Your Call at $0.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BMEA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BMEA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $0.76 (+18.8%)
📌 Pinned Debate

A buy-rated initiation from Brookline Capital and a 7% after-hours climb point to near-term sentiment support ahead of BMF-650 Phase I

Don't sleep on BMEA's setup in Health Care. A buy-rated initiation from Brookline Capital and a 7% after-hours climb point to near-term sentiment support ahead of BMF-650 Phase I results.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (30/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $0.64 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.51 (-20.3%)
Spot @ $0.64

A -35% ROIC, 0% FCF yield, and a 2/9 Piotroski F-Score indicate a cash-burning business with weak forensic fundamentals.

Sitting on the sidelines or leaning short BMEA above $0.64. A -35% ROIC, 0% FCF yield, and a 2/9 Piotroski F-Score indicate a cash-burning business with weak forensic fundamentals.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.24.

LIVE TAPE